SCGB1A1 and chronic obstructive pulmonary disease: Targeting this pathway, either by restoring CC16 levels or modulating SCGB1A1 activity, may offer promising avenues for developing specific personalized medicine-based therapeutic approaches and novel treatment strategies for COPD management.